Bach Pharma, Inc.
Records under this name other than patents Bach Pharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Bach Pharma, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,732,043 | Process for preparing 5-amino-2,3-dihydrophthalazine-1,4-dione monosodium salt Lapsed on the fee record Ended Aug 15, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 15, 2025 | From the USPTO record |
| US 9,358,225 | Method for treating neurodegeneration using a p38MAPK inhibitor Lapsed on the fee record Ended Jun 7, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jun 7, 2024 | From the USPTO record |
| US 9,968,602 | Modulation of cell fates and activities by phthalazinediones Term ended Term ended Sep 4, 2023 · From the USPTO record | Term ended | Term ended Sep 4, 2023 | From the USPTO record |
| US 6,953,799 | Modulation of cell fates and activities by diketo phthalazines Term ended Term ended Jan 11, 2023 · From the USPTO record | Term ended | Term ended Jan 11, 2023 | From the USPTO record |
| US 8,895,555 | Methods of treating intestinal diseases and inflammatory conditions related to HIV-AIDS Lapsed on the fee record Ended Nov 25, 2022 · From the USPTO record | Lapsed on the fee record | Ended Nov 25, 2022 | From the USPTO record |
| US 7,326,690 | Modulation of cell fates and activities by phthalazinediones Term ended Term ended Oct 30, 2022 · From the USPTO record | Term ended | Term ended Oct 30, 2022 | From the USPTO record |
| US 7,691,819 | Modulation of cell fates and activities by phthalazinediones Lapsed on the fee record Ended Apr 6, 2022 · From the USPTO record | Lapsed on the fee record | Ended Apr 6, 2022 | From the USPTO record |